AllSci News
Novomedix wins $2.98 million NCI contract to advance oral drug for pediatric solid tumors
Novomedix, a San Diego-based for-profit company, has received a $2.98 million SBIR Phase II contract from the National Cancer Institute to advance a...
Akeso's first-in-class trispecific antibody hits ILT2, ILT4, and CSF1R to dismantle myeloid immunosuppression in solid tumors
Akeso's trispecific antibody AK150, which simultaneously targets the immunosuppressive receptors ILT2, ILT4, and CSF1R, has received Investigational New...
Roche halts emugrobart development in spinal muscular atrophy after MANATEE study fails
Roche has discontinued development of emugrobart (GYM329), an investigational anti-myostatin antibody, in spinal muscular atrophy after Part 1 of the Phase...
PBS293-MMAE preclinical data from Promatix Biosciences show promise in colorectal cancer models
UK-based Promatix Biosciences announced preclinical data for PBS293-MMAE, a first-in-class cis-bispecific antibody-drug conjugate targeting both EGFR and...
Cyrano Therapeutics' CYR-064 shows positive Phase II results in persistent post-viral smell loss
Florida-based Cyrano Therapeutics announced positive topline results from its Phase II FLAVOR trial evaluating CYR-064, an intranasal broad-spectrum...
Dizal's sunvozertinib beats chemotherapy in Phase III first-line EGFR exon 20 insertion NSCLC trial
Dizal (SSE:688192) reported that its Phase III WU-KONG28 trial of sunvozertinib (Zegfrovy) met its primary endpoint in first-line NSCLC harboring EGFR exon...
kyron.bio and Servier partner on precision glycosylation of antibody therapeutics
Paris-based kyron.bio, a seed-stage biotechnology company specializing in precision glycosylation of antibody therapeutics, and Servier, the privately held...
Immunic raises USD 400m in private placement to advance multiple sclerosis programs
Immunic, Inc. (Nasdaq: IMUX), a New York-based biotechnology company, announced a private placement of up to USD 400 million in gross proceeds. The Immunic...
Roche's Gazyva achieves positive phase III results in primary membranous nephropathy trial
Roche announced that the Phase III MAJESTY study evaluating Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy met its primary endpoint, with...
argenx reports positive Phase 3 results for efgartigimod in ocular myasthenia gravis trial
Netherlands-based argenx SE announced positive topline results from the Phase 3 ADAPT OCULUS trial evaluating VYVGART (efgartigimod alfa and...
Adial Pharmaceuticals and Molteni Farmaceutici sign USD 60m. AD04 alcohol disorder deal for Europe
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company headquartered in Glen Allen, Virginia, and Molteni Farmaceutici, a...
Priavoid presents blinded interim safety data for PRI-002 in Alzheimer's disease Phase II trial
Priavoid GmbH, a Dusseldorf-based biotech, presented blinded interim safety data from its ongoing Phase II trial of PRI-002 in Alzheimer's disease at the...
Centivax Doses First Participants in Phase 1 Trial of Centi-Flu 01 Universal Influenza Vaccine
Centivax, Inc., a South San Francisco–based biotechnology company, has dosed the first participants in a Phase 1A clinical trial of Centi-Flu 01, a...
PharmaMar and Globant collaborate on multi-agent AI for oncology research prioritization
PharmaMar, a Madrid-based company focused on marine-derived oncology therapeutics, and Globant, a Buenos Aires-founded digital and AI services firm listed...
Eupraxia Pharmaceuticals raises USD 55m in public offering
Canada-based Eupraxia Pharmaceuticals Inc. (Nasdaq: EPRX / TSX: EPRX) announced the pricing of a public offering of common shares and pre-funded warrants...
The AllSci Brief
Systematic R&D and deal news. Daily.